Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Lancet Oncol. 2016 Aug 27;17(10):1435–1444. doi: 10.1016/S1470-2045(16)30227-3

Figure 2. Progression-free survival in post-prostatectomy (A) and metastatic (B) validation cohorts according to HSD3B1 genotype.

Figure 2

Progression-free survival (PFS) diminished according to HSD3B1 genotype in both validation cohorts. In the post-prostatectomy cohort (Panel A), median PFS was 3.3 years in homozygous wild-type men (95% CI, 1.9 to 4.9); 2.8 years in heterozygotes (95% CI, 2.1 to 5.1); and 0.9 years in homozygous variant men (95% CI, 0.2 to 2.6; P=0.0022). Homozygous variant men had a 3.4-times risk of progression relative to homozygous wild-type men (95% CI, 1.6 to 7.0; P=0.0013), while the corresponding hazard ratio for heterozygous men was 1.0 (95% CI, 0.7 to 1.7; P=0.85). In the metastatic cohort (Panel B), median PFS was likewise longest in homozygous wild-type men (1.8 years; 95% CI, 1.2 to 2.5) and shortest in homozygous variant men (0.8 years; 95% CI, 0.3 to 1.6; P=0.024). The corresponding hazard ratio for progression was 2.0 (95% CI 1.1 to 3.8; P=0.027). Heterozygous men had an intermediate PFS of 1.4 years (95% CI, 1.0 to 1.8) and hazard ratio for progression of 1.1 (95% CI 0.8 to 1.5; P=0.38).